Activity – Talk Bio

FDA Lifts Partial Hold on Merck and Daiichi Sankyo’s B7-H3 ADC Trial for Lung Cancer[6]

3 days ago talkbio0Tagged CD276 gene, Daiichi, Deruxtecan, I-DXd, IDeate-Lung02, ifinatamab, Lifting, Merck, Sankyo, Small cell carcinoma of lung, therapeutic autologous dendritic cells, United States Food and Drug Administration

FDA; partial hold lifted; Merck; Daiichi Sankyo; ifinatamab deruxtecan; I-DXd; B7-H3 ADC; small cell lung cancer; IDeate-Lung02

Dr Melanie Ivarsson Appointed CEO of Health Data Research Service

3 days ago talkbio0Tagged Appointments, Barakat syndrome, CEO, health data, Health Data Research Service, Medical Research activity, Melanie Ivarsson, UK

Dr Melanie Ivarsson; Health Data Research Service; HDRS; CEO appointment; UK health data; medical research

Syncromune Appoints Dr. Stephen P. Dale as Chief Medical Officer

1 week ago talkbio0Tagged Appointments, Biological Factors, Chronic multifocal osteomyelitis, Neoplasms, Stephen P. Dale, SYNC-T, Syncromune

Syncromune; Stephen P. Dale; CMO; appointment; oncology; SYNC-T; biopharmaceutical

Avicanna Announces Changes to its Board of Directors

2 weeks ago talkbio0Tagged Appointments, Avicanna, board changes, Michael Kott, Paul Fornazzari, resignation

Avicanna; board changes; Michael Kott; Paul Fornazzari; appointment; resignation

Gilead’s $35M Herpes Deal with Assembly Biosciences and Recent FDA Approvals

3 weeks ago talkbio0Tagged ABI-5366, Assembly (construction), Boehringer, Gilead, Herpes NOS, Herpes Simplex Infections, Roche (company), United States Food and Drug Administration

Gilead; Assembly Biosciences; herpes; HSV; ABI-1179; ABI-5366; FDA; Boehringer; Roche

Jim Lang Appointed to the Board of Directors of Halozyme Therapeutics

4 weeks ago talkbio0Tagged Appointments, Bench International, Biological Factors, BioVie, board of directors, Corporate governance, drug delivery platform, election, Halozyme Therapeutics, Jim Lang

Jim Lang; Halozyme Therapeutics; Board of Directors; appointment; election; Bench International; biopharmaceutical; drug delivery platform; corporate governance; OptimizeRx; BioVie

Ankyra Therapeutics Appoints Sailaja Battula, PhD as Chief Scientific Officer

1 month ago talkbio0Tagged Ankyra Therapeutics, Appointments, Biotechnology, CSO, immuno-oncology, Sailaja Battula

Ankyra Therapeutics; Sailaja Battula; CSO appointment; immuno-oncology; biotechnology

The Endpoints 100: Biotech CEOs are feeling more upbeat about the road ahead

1 month ago talkbio0Tagged Attitude, biopharma executives, CEOs, dealmaking, E100 survey, Endpoints, Industry, IPO, Market, Recovery - action, reorganization, Sentiment, Trump administration, United States Food and Drug Administration, Window (physical object)

Endpoints 100; E100 survey; biotech CEOs; biopharma executives; industry sentiment; market recovery; dealmaking; IPO window; Trump administration; FDA reorganization; tariffs; 2025 outlook

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

1 month ago talkbio0Tagged ARIA risk, Binding action, Biological Markers, clinical outcomes, Dental Plaque, oligomer selectivity, Phase 1b Trial, PMN310, PRECISE-AD trial, ProMIS Neurosciences, Toxic Oligomers, vascular deposit binding

ProMIS Neurosciences; PMN310; toxic oligomers; ARIA risk; PRECISE-AD trial; peer-reviewed publication; oligomer selectivity; plaque binding; vascular deposit binding; phase 1b trial; biomarkers; clinical outcomes

SanegeneBio raises over $110M Series B after Lilly RNAi deal

1 month ago talkbio0Tagged clinical-stage assets, eli lilly, extrahepatic RNAi, Fund Raising, Lilly collaboration, liver-targeted RNAi, Metabolic Diseases, RNA, RNA Interference, SanegeneBio, Series B financing

SanegeneBio; Series B financing; $110 million; Eli Lilly; RNA interference; RNAi therapeutics; metabolic diseases; Lilly collaboration; clinical-stage assets; liver-targeted RNAi; extrahepatic RNAi; biotech fundraising 2025